Bacteriophage Therapy of Difficult-to-treat Infections

Background: In 2008, the Queen Astrid military hospital (QAMH) re-initiated treatments with phages, in selective cases. The QAMH implemented a Phage Therapy Coordination Center (PTCC), which is an essential step in the re-introduction of safe and efficient phage therapy, in collaboration with several hospitals and the public health authorities.

In 2018, Belgium implemented a pragmatic phage therapy framework that centers on the magistral preparation (compounding pharmacies in the US) of tailor-made phage medicines, which paved the way for a broader and more structured application of phages in Belgium.

The PTCC facilitated phage therapy in about 110 difficult-to-treat infections in patients in Belgium, but also abroad, as the Belgian is increasingly finding appeal in other European countries.

Objective: The goal of this study is to retrospectively analyse observational data on the first one hundred consecutive phage therapy cases of difficult-to-treat infections, which were facilitated by the PTCC. The knowledge gained from these cases would help physicians to select effective treatment protocols and to design new clinical trials.

Study design: A de-identified database consisting of demographical, microbiological and clinical observational data on 100 consecutive phage applications performed between 01/01/2008 and 31/05/22 will be retrospectively analyzed. A list of the parameters that will be analyzed can be found in addendum 1.

According to the EU Regulation No 536/2014 (Clinical Trials Regulation) and its transposition to Belgian Law, the retrospective non-interventional study of the de-identified existing phage therapy database is not considered as a an experiment on the human person and does not require informed consent.

The R software environment will be used to analyze the correlation between treatment variables, including the applied phage products (used in combination with antibiotics or not), clinical protocols (proposed by the PTCC, and mostly based on the experiences of the Eliava Institute in the Republic of Georgia), infection types, possible adverse events, clinical outcome (improvement or not), and microbial eradication.

Results will be translated into practical recommendations, which will help physicians to select effective treatment protocols and to design new clinical trials.

The quality control of the used phage products was performed by Sciensano (formerly known as the Belgian Scientific Institute for Public Health) and clinical applications were performed in 34 hospitals in 12 countries (Belgium, United Kingdom, Germany, France, The Netherlands, Switzerland, Latvia, Tunisia, Spain, Portugal, Italy and Austria), under four different regulatory frameworks:

• Standard of care with magistral phage preparations (since 2018)
• Article 37 (unproven interventions in clinical practice) of the Declaration of Helsinki
• Standard of care with unlicensed medicines (in the United Kingdom)
• "Autorisation Temporaire d'Utilisation" (ATU) (in France) Written informed consent for the clinical application of phages was obtained from the involved patients or their legal representatives according to local provisions. Where warranted, local ethical committee approval for the application of phage therapy was obtained.

The data was obtained through the patients' treating physicians and their authorisation to analyse this data, and a possible scientific publication of the results of this study, will be obtained.

The study is conducted at the QAMH in Brussels under the responsibility and supervision of Dr. Sarah Djebara of the PTCC of the QAMH.

Addendum 1. Observational data on the 100 consecutive phage therapy cases

Demographics*:

Country in which the therapy was performed/ Year in which phage therapy was initiated/ Patient gender/ Patient age

Infection:

Primary infection type/ Secondary infection type/ Acute or chronic infection?/ Additional relevant information/ Organisms/ Antibiotic resistance profile of the targeted strain(s)

Phage product:

Phage name(s)/ Diluent/ Concentration (pfu/ml)

Treatment:

Intraoperative application/ Application route 1 (Dose/Duration)/ Application route 2 (Dose/Duration)/ Concomitant antibiotic treatment/ Ambulatory or hospitalized?

Adverse events:

Adverse event/Duration/Severity/Relationship to phage treatment?/Action

Clinical outcome:

Clinical improvement?/Microbial eradication?/Clinical comment (additional relevant information)

Regulatory context

Published case? If yes, reference

• The demographics data are separated from the individual cases

Inclusion criteria

• Patients with difficult-to-treat bacterial infections

Exclusion criteria

• None